Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30541946 | 1.00 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BHRH3POLB | |
| Hydrochloric Acid SCHEMBL31150738 | 0.98 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BHRH3POLB | |
| Hydrochloric Acid SCHEMBL16496302 | 0.98 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BHRH3POLB | |
| SCHEMBL20602894 | 0.80 | MEN1 (0.39) | ADRA1DADRA1AADRA1BPOLBLMNA | |
| SCHEMBL20620253 | 0.80 | TDP2 (0.44) | ADRA1DADRA1AADRA1BHRH3NPY5R | |
| SCHEMBL20620254 | 0.80 | KDM4E (0.46) | LMNAALDH1A1MAPTHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL23359125 | 0.79 | TDP2 (0.43) | ADRA1DADRA1AADRA1BHRH3MAOA | |
| SCHEMBL12836261 | 0.79 | ADRA1D (0.58) | ADRA1DADRA1AADRA1BHRH3POLB | |
| SCHEMBL231585 | 0.77 | OPRD1 (0.49) | LMNAHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL20620282 | 0.77 | HTR2A (0.42) | ADRA1DADRA1AADRA1BHRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230355609-A1 | Spirolactone Compounds | QUIXGEN, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11541046-B2 | Spirolactone compounds | QUIXGEN, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210145822-A1 | Novel Spirolactone Compounds | QUIXGEN, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2007136605-A2 | ARYL-FUSED SPIROCYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-6720324-B2 | THERAPY FOR EATING DISORDERS, SEXUAL DISORDERS, PSYCHOLOGICAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-10 | — | — | US | disclosed |
| US-5652235-A | Method of using spiro piperidines to promote the release of growth hormone | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5536716-A | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541046-B2 | Spirolactone compounds | ACACA, AKR1C2, AKR1A1 | ADRA1D 766/4885ADRA1A 688/4885ADRA1B 687/4885 |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 247/4885ADRA1A 224/4885ADRA1B 306/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 100/4885ADRA1A 88/4885ADRA1B 143/4885 |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | ADRA1D 699/4885ADRA1A 235/4885ADRA1B 1155/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | ADRA1D 730/4885ADRA1A 326/4885ADRA1B 1232/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1D 247/4885ADRA1A 224/4885ADRA1B 306/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ADRA1D 250/4885ADRA1A 330/4885ADRA1B 287/4885 |
| US-20030069261-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | ADRA1D 149/4885ADRA1A 161/4885ADRA1B 156/4885 |
| US-20210145822-A1 | Novel Spirolactone Compounds | ACACA, HSD17B10, AKR1C2 | ADRA1D 658/4885ADRA1A 666/4885ADRA1B 641/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ADRA1D 250/4885ADRA1A 330/4885ADRA1B 287/4885 |
| US-20230355609-A1 | Spirolactone Compounds | ACACA, AKR1C2, AKR1A1 | ADRA1D 766/4885ADRA1A 688/4885ADRA1B 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.